An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Expanding diagnostics footprint in East India
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Tislelizumab is now approved in nine indications in China
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Subscribe To Our Newsletter & Stay Updated
